// App-Quantinova.ai

e13015 : Trastuzumab biosimilar (Kanjinti) in breast cancer patients: One-center retrospective observational study.

Researchers

Presenter

  • Agnieszka I. Jagiello-Gruszfeld

Principal Investigators

  • Izabela Lemanska

  • Elzbieta Brewczynska

  • Katarzyna Pogoda

  • Roman Dubianski

  • Renata Sienkiewicz

  • Ewa Szombara

  • Beata Jagielska

  • Zbigniew Nowecki

Medical Centers

  • Breast Cancer and Reconstrucive Surgery Dept., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

Locations

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab biosimilar

  • CT-P6

  • Carboplatin

  • Trastuzumab

  • Pertuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Observational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved